BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 09:29 (598 d 08:56 ago) – Posting: # 20530
Views: 1,110

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 7 (0 registered, 7 guests [including 2 identified bots]).
Forum time: Monday 18:25 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5